Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

p in a wide variety of diseases where sleep improvement may be beneficial."

"A majority of insomnia patients, especially the elderly and those with comorbid conditions, have difficulty staying asleep throughout the night," said Thomas Roth, Ph.D., Director of Research, Chief of Sleep Medicine for the Henry Ford Hospital Sleep Disorders and Research Center. "These data show that ITI-007 can maintain sleep without impairing next day functioning."

SUMMARY OF PHASE II SMI RESULTS

ITI-007 is an orally available investigational new drug being developed at low doses for the treatment of insomnia characterized by difficulty staying asleep, also referred to as sleep maintenance insomnia, and for insomnia associated with psychiatric disorders such as depression and post-traumatic stress disorder, and insomnia associated with neurologic disorders such as traumatic brain injury, Parkinson's disease, Alzheimer's disease and mild cognitive impairment. Previously announced interim results showed that patients with SMI treated with ITI-007 experienced dose-dependent increases in slow wave sleep (SWS) and dramatic decreases in wake after sleep onset (WASO) as determined by PSG. The final analysis (N=19) confirmed these results, meeting the primary and key secondary endpoints of the trial, and extended the findings to demonstrate remarkable efficacy in this patient population.

This Phase II trial was a double-blind, placebo controlled, 4-way crossover design comparing placebo to 3 doses of ITI-007 (1 mg, 5 mg and 10 mg) in patients with SMI. Analysis of key objectives in this study indicated that ITI-007 dose-dependently and significantly increased SWS (p=0.002) and decreased WASO (p=0.001). Consistent with the significant decrease in WASO, ITI-007 showed a statistical trend to decrease the number of awakenings (p=0.071). These large decreases in WASO also were reflected in the PSG recordings by increased tot
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... -- In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... more than 15 prominent landmarks red throughout the ... Zakim Bridge and Prudential Tower, Chicago,s ... and Denver,s Coors Field . ... and coincide with hemophilia community events in a dozen locations ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... by a group at the University of Maryland (UMd), ... research and an age-old metallurgy technique to produce an ... class of sensors and micromechanical devices controlled by magnetism.* ... notable, among other things, for not using rare-earth elements ...
... Nov. 23, 2011  Puma Biotechnology, Inc., a development stage ... the Company completed the second tranche of its $60 ... October 5, 2011, Puma sold approximately 14.7 million shares ... purchase price of $3.75 per share, resulting in gross ...
... Modern Mobility Aids, Inc. (OTCBB: MDRM) (the "Company") ... financing required to execute its closing agreement to acquire ... ("LumiGene"). Modern Mobility Aids, Inc. is a ... and development in the Bio-Pharma sector as well as ...
Cached Biology Technology:New magnetic-field-sensitive alloy could find use in novel micromechanical devices 2Puma Biotechnology Announces Completion of Private Placement 2Puma Biotechnology Announces Completion of Private Placement 3Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 3
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... , This release is available in Spanish ... at the Institute for Research in Biomedicine (IRB Barcelona), reveal ... the one known to date. Found in the cell membrane, ... of genes that make the cell divide, grow, migrate, specialise ...
... Helicobacter pylori , a bacterium found in about 50% of ... cancer. In an article for F1000 Medicine Reports , Seiji ... pylori infections Infection by the H. pylori ... do not have symptoms, but many develop problems including stomach ulcers. ...
... of Minnesota have created a molecular image of a system ... a breakthrough for biology and could provide insights to minimize ... electricity around the country. The research, led by ... Sciences, is published in the March 12 issue of ...
Cached Biology News:Opposing functions of a key molecule in the development of organisms 2Opposing functions of a key molecule in the development of organisms 3Preventing gastric cancer with antibiotics 2U of Minnesota researcher discovers how electricity moves through cells 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: